HQ BaselineTechnology
The 15-Minute Blood Test for Brain Injuries: What Abbott's FDA-Cleared Concussion Test Actually Tells You
Genuinely exciting technology — but it's critical to understand what this test does and doesn't do.
In April 2024, Abbott received FDA clearance for a whole blood rapid test that helps assess concussion at the bedside. As announced in Abbott’s official press release, the i-STAT TBI Plasma test measures two brain-specific proteins — GFAP (glial fibrillary acidic protein) and UCH-L1 (ubiquitin C-terminal hydrolase L1) — from a simple finger prick and returns results in approximately 15 minutes.
Why it’s a legitimate advance
This is genuinely exciting technology. These proteins are released into the bloodstream when brain cells are damaged, and their presence can help clinicians determine whether a patient with a head injury needs a CT scan to rule out intracranial bleeding. The TRACK-TBI study (Transforming Research and Clinical Knowledge in TBI), a multi-center research initiative funded by the NIH and published in The Lancet Neurology, provided the clinical validation data supporting this test.
What it does — and doesn’t — do
But it’s critical to understand what this test does and doesn’t do. The test helps rule out the need for CT imaging — potentially reducing unnecessary radiation exposure and emergency department costs. It does not diagnose concussion. It does not assess cognitive function, balance, or vestibular-ocular performance. It does not replace baseline testing.
The limitations
According to research published in Psychiatric News and the FDA clearance documentation, the test has significant limitations:
- Only validated for adults.
- Must be administered within 24 hours of injury.
- Significantly less accurate in older adults — the population at highest risk for serious TBI outcomes.
Biomarkers and baselines answer different questions
Blood biomarkers and baseline cognitive testing address fundamentally different clinical questions. Biomarkers answer: “Is there structural brain damage that might need imaging?” Baselines answer: “Has this person’s brain function changed from their healthy state?” Both are valuable. Neither replaces the other.
At Headquarters, we view blood biomarkers as a promising complement to our baseline testing approach, not a replacement. As these technologies mature and become available outside the emergency department setting, we’ll integrate them where the evidence supports clinical utility. For the broader landscape of new tools, see our 7-technology overview.